Complete report details @ https://www.wiseguyreports.com/reports/649780-seborrhea-pipeline-review-h2-2016
Summary
‘Seborrhea - Pipeline
Review, H2 2016’, provides an overview of the Seborrhea pipeline landscape.
The report provides comprehensive information on the
therapeutics under development for Seborrhea, complete with analysis by stage
of development, drug target, mechanism of action (MoA), route of administration
(RoA) and molecule type. The report also covers the descriptive pharmacological
action of the therapeutics, its complete research and development history and
latest news and press releases. Additionally, the report provides an overview
of key players involved in therapeutic development for Seborrhea and features
dormant and discontinued projects.
Report features investigational drugs from across globe covering
over 20 therapy areas and nearly 3,000 indications. The report is built using
data and information sourced from proprietary databases, company/university
websites, clinical trial registries, conferences, SEC filings, investor
presentations and featured press releases from company/university sites and
industry-specific third party sources. Drug profiles featured in the report
undergoes periodic review following a stringent set of processes to ensure that
all the profiles are updated with the latest set of information. Additionally,
various dynamic tracking processes ensure that the most recent developments are
captured on a real time basis.
The report helps in identifying and tracking emerging players in
the market and their portfolios, enhances decision making capabilities and
helps to create effective counter strategies to gain competitive advantage.
Scope
Request a sample report @ https://www.wiseguyreports.com/sample-request/649780-seborrhea-pipeline-review-h2-2016
- The report provides a snapshot of the global therapeutic
landscape of Seborrhea
- The report reviews pipeline therapeutics for Seborrhea by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Seborrhea therapeutics and enlists all their major and minor projects
- The report assesses Seborrhea therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Seborrhea
- The report reviews pipeline therapeutics for Seborrhea by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Seborrhea therapeutics and enlists all their major and minor projects
- The report assesses Seborrhea therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Seborrhea
Reasons
to buy
Make an
enquiry before buying this Report @ https://www.wiseguyreports.com/enquiry/649780-seborrhea-pipeline-review-h2-2016
- Gain strategically significant competitor information,
analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Seborrhea
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Seborrhea pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Seborrhea
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Seborrhea pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Check
Discount on this report @ https://www.wiseguyreports.com/check-discount/649780-seborrhea-pipeline-review-h2-2016
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Seborrhea Overview 6
Therapeutics Development 7
Pipeline Products for Seborrhea - Overview 7
Seborrhea - Therapeutics under Development by Companies 8
Seborrhea - Pipeline Products Glance 9
Late Stage Products 9
Clinical Stage Products 10
Early Stage Products 11
Seborrhea - Products under Development by Companies 12
Seborrhea - Companies Involved in Therapeutics Development 13
Aclaris Therapeutics Inc 13
Amorepacific Corporation 14
Biomar Microbial Technologies 15
EpiPharm AG 16
Phosphagenics Limited 17
Seborrhea - Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Target 19
Assessment by Mechanism of Action 21
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Drug Profiles 26
artemether - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
hydrogen peroxide - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
IB-07A081 - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
IB-07A085 - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
ketoconazole - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
PAC-14028 - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
Seborrhea - Dormant Projects 34
Seborrhea - Discontinued Products 35
Seborrhea - Product Development Milestones 36
Featured News & Press Releases 36
Jul 25, 2016: Aclaris Therapeutics Completes Enrollment of Phase 3 Pivotal Trials of A-101 for the Treatment of Seborrheic Keratosis; Provides Update on Clinical Programs 36
Jan 19, 2016: Aclaris Therapeutics Initiates Phase 3 Clinical Trials of A-101 for the Treatment of Seborrheic Keratosis 36
Mar 17, 2015: Aclaris Therapeutics’ Lead Drug Candidate A-101 Achieves Statistically Significant Results in Third Phase 2 Clinical Trial for Seborrheic Keratosis, a Common Type of Benign Skin Tumor 36
Jan 27, 2015: Aclaris Therapeutics Announces Positive Results from Phase 2b Clinical Trial of A-101 for the Removal of Seborrheic Keratosis, a Common Type of Benign Skin Tumor 37
Jun 30, 2014: Aclaris Therapeutics Announces Positive Results from Phase 2 Clinical Trial of A-101 for the Removal of Seborrheic Keratosis, a Common Type of Skin Tumor 38
Appendix 39
Methodology 39
Coverage 39
Secondary Research 39
Primary Research 39
Expert Panel Validation 39
Contact Us 39
Disclaimer 40
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Seborrhea Overview 6
Therapeutics Development 7
Pipeline Products for Seborrhea - Overview 7
Seborrhea - Therapeutics under Development by Companies 8
Seborrhea - Pipeline Products Glance 9
Late Stage Products 9
Clinical Stage Products 10
Early Stage Products 11
Seborrhea - Products under Development by Companies 12
Seborrhea - Companies Involved in Therapeutics Development 13
Aclaris Therapeutics Inc 13
Amorepacific Corporation 14
Biomar Microbial Technologies 15
EpiPharm AG 16
Phosphagenics Limited 17
Seborrhea - Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Target 19
Assessment by Mechanism of Action 21
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Drug Profiles 26
artemether - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
hydrogen peroxide - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
IB-07A081 - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
IB-07A085 - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
ketoconazole - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
PAC-14028 - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
Seborrhea - Dormant Projects 34
Seborrhea - Discontinued Products 35
Seborrhea - Product Development Milestones 36
Featured News & Press Releases 36
Jul 25, 2016: Aclaris Therapeutics Completes Enrollment of Phase 3 Pivotal Trials of A-101 for the Treatment of Seborrheic Keratosis; Provides Update on Clinical Programs 36
Jan 19, 2016: Aclaris Therapeutics Initiates Phase 3 Clinical Trials of A-101 for the Treatment of Seborrheic Keratosis 36
Mar 17, 2015: Aclaris Therapeutics’ Lead Drug Candidate A-101 Achieves Statistically Significant Results in Third Phase 2 Clinical Trial for Seborrheic Keratosis, a Common Type of Benign Skin Tumor 36
Jan 27, 2015: Aclaris Therapeutics Announces Positive Results from Phase 2b Clinical Trial of A-101 for the Removal of Seborrheic Keratosis, a Common Type of Benign Skin Tumor 37
Jun 30, 2014: Aclaris Therapeutics Announces Positive Results from Phase 2 Clinical Trial of A-101 for the Removal of Seborrheic Keratosis, a Common Type of Skin Tumor 38
Appendix 39
Methodology 39
Coverage 39
Secondary Research 39
Primary Research 39
Expert Panel Validation 39
Contact Us 39
Disclaimer 40
Contact US:
NORAH TRENT
Partner Relations
& Marketing Manager
sales@wiseguyreports.com
Ph:
+1-646-845-9349 (US)
Ph:
+44 208 133 9349 (UK)
No comments:
Post a Comment